HIV‐2EU : Supporting Standardized HIV‐2 DrugResistance Interpretation in Europe

Charpentier, Charlotte;Camacho, Ricardo;Ruelle, Jean;Kaiser, Rolf;Obermeier, Martin;et.al.
(2013) Clinical Infectious Diseases — Vol. 56, n° 11, p. 1654-1658 (1 june) (2013)

Files

ClinInfectDis-2013-Charpentier-1654-8.pdf
  • Restricted Access
  • Adobe PDF
  • 981.18 KB
Request a copy

Details

Authors
  • Charpentier, CharlotteUniversité Paris Diderot
    Author
  • Camacho, RicardoUniversidade Nova de Lisboa e Laboratorio de Biologia Molecular
    Author
  • Ruelle, JeanUCLouvain
    Author
  • Kaiser, RolfUniversity of Cologne
    Author
  • Obermeier, MartinMedizinisches Labor Dr. Berg, Berlin
    Author
Show more
Abstract
Considering human immunodeficiency virus type 2 (HIV-2) phenotypic data and experience from HIV type 1 and from the follow-up of HIV-2–infected patients, a panel of European experts voted on a rule set for interpretation of mutations in HIV-2 protease, reverse transcriptase, and integrase and an automated tool for HIV-2 drug resistance analyses freely available on the Internet
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Charpentier, C., Camacho, R., Ruelle, J., Kaiser, R., Eberle, J., Gürtler, L., Pironti, A., Stürmer, M., Brun-Vézinet, F., Descamps, D., & Obermeier, M. (2013). HIV‐2EU : Supporting Standardized HIV‐2 DrugResistance Interpretation in Europe. Clinical Infectious Diseases, 56(11), 1654-1658 (1 june). https://doi.org/10.1093/cid/cit104 (Original work published 2013)